These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

195 related items for PubMed ID: 16406316

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Anomalously phosphorylated tau and Abeta fragments in the CSF correlates with cognitive impairment in MCI subjects.
    Maccioni RB, Lavados M, Guillón M, Mujica C, Bosch R, Farías G, Fuentes P.
    Neurobiol Aging; 2006 Feb; 27(2):237-44. PubMed ID: 16399209
    [Abstract] [Full Text] [Related]

  • 3. Value of CSF beta-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment.
    Hampel H, Teipel SJ, Fuchsberger T, Andreasen N, Wiltfang J, Otto M, Shen Y, Dodel R, Du Y, Farlow M, Möller HJ, Blennow K, Buerger K.
    Mol Psychiatry; 2004 Jul; 9(7):705-10. PubMed ID: 14699432
    [Abstract] [Full Text] [Related]

  • 4. CSF markers in Alzheimer disease patients are not related to the different degree of cognitive impairment.
    Stefani A, Martorana A, Bernardini S, Panella M, Mercati F, Orlacchio A, Pierantozzi M.
    J Neurol Sci; 2006 Dec 21; 251(1-2):124-8. PubMed ID: 17097109
    [Abstract] [Full Text] [Related]

  • 5. Diagnosing prodromal Alzheimer's disease: role of CSF biochemical markers.
    Parnetti L, Lanari A, Silvestrelli G, Saggese E, Reboldi P.
    Mech Ageing Dev; 2006 Feb 21; 127(2):129-32. PubMed ID: 16274728
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Levels of ApoE in cerebrospinal fluid are correlated with Tau and 24S-hydroxycholesterol in patients with cognitive disorders.
    Shafaati M, Solomon A, Kivipelto M, Björkhem I, Leoni V.
    Neurosci Lett; 2007 Sep 25; 425(2):78-82. PubMed ID: 17822846
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. CSF levels of heart fatty acid binding protein are altered during early phases of Alzheimer's disease.
    Chiasserini D, Parnetti L, Andreasson U, Zetterberg H, Giannandrea D, Calabresi P, Blennow K.
    J Alzheimers Dis; 2010 Sep 25; 22(4):1281-8. PubMed ID: 20930282
    [Abstract] [Full Text] [Related]

  • 11. Cerebrospinal fluid amyloid beta(1-42) levels in the mild cognitive impairment stage of Alzheimer's disease.
    Maruyama M, Arai H, Sugita M, Tanji H, Higuchi M, Okamura N, Matsui T, Higuchi S, Matsushita S, Yoshida H, Sasaki H.
    Exp Neurol; 2001 Dec 25; 172(2):433-6. PubMed ID: 11716567
    [Abstract] [Full Text] [Related]

  • 12. The diagnostic value of tau protein, beta-amyloid (1-42) and their ratio for the discrimination of alcohol-related cognitive disorders from Alzheimer's disease in the early stages.
    Kapaki E, Liappas I, Paraskevas GP, Theotoka I, Rabavilas A.
    Int J Geriatr Psychiatry; 2005 Aug 25; 20(8):722-9. PubMed ID: 16035118
    [Abstract] [Full Text] [Related]

  • 13. Multiplexed quantification of dementia biomarkers in the CSF of patients with early dementias and MCI: a multicenter study.
    Lewczuk P, Kornhuber J, Vanderstichele H, Vanmechelen E, Esselmann H, Bibl M, Wolf S, Otto M, Reulbach U, Kölsch H, Jessen F, Schröder J, Schönknecht P, Hampel H, Peters O, Weimer E, Perneczky R, Jahn H, Luckhaus C, Lamla U, Supprian T, Maler JM, Wiltfang J.
    Neurobiol Aging; 2008 Jun 25; 29(6):812-8. PubMed ID: 17239996
    [Abstract] [Full Text] [Related]

  • 14. Levels of beta-secretase (BACE1) in cerebrospinal fluid as a predictor of risk in mild cognitive impairment.
    Zhong Z, Ewers M, Teipel S, Bürger K, Wallin A, Blennow K, He P, McAllister C, Hampel H, Shen Y.
    Arch Gen Psychiatry; 2007 Jun 25; 64(6):718-26. PubMed ID: 17548753
    [Abstract] [Full Text] [Related]

  • 15. Soluble amyloid precursor proteins in the cerebrospinal fluid as novel potential biomarkers of Alzheimer's disease: a multicenter study.
    Lewczuk P, Kamrowski-Kruck H, Peters O, Heuser I, Jessen F, Popp J, Bürger K, Hampel H, Frölich L, Wolf S, Prinz B, Jahn H, Luckhaus Ch, Perneczky R, Hüll M, Schröder J, Kessler H, Pantel J, Gertz HJ, Klafki HW, Kölsch H, Reulbach U, Esselmann H, Maler JM, Bibl M, Kornhuber J, Wiltfang J.
    Mol Psychiatry; 2010 Feb 25; 15(2):138-45. PubMed ID: 18663368
    [Abstract] [Full Text] [Related]

  • 16. Subcortical vascular dementia biomarker pattern in mild cognitive impairment.
    Bjerke M, Andreasson U, Rolstad S, Nordlund A, Lind K, Zetterberg H, Edman A, Blennow K, Wallin A.
    Dement Geriatr Cogn Disord; 2009 Feb 25; 28(4):348-56. PubMed ID: 19864909
    [Abstract] [Full Text] [Related]

  • 17. [CSF levels of total tau protein in patients with mild cognitive impairment and Alzheimer's disease].
    Kaiser E, Schönknecht P, Hunt A, Thomann PA, Pantel J, Schröder J.
    Z Gerontol Geriatr; 2008 Dec 25; 41(6):497-501. PubMed ID: 18327693
    [Abstract] [Full Text] [Related]

  • 18. Whole-brain atrophy rate and CSF biomarker levels in MCI and AD: a longitudinal study.
    Sluimer JD, Bouwman FH, Vrenken H, Blankenstein MA, Barkhof F, van der Flier WM, Scheltens P.
    Neurobiol Aging; 2010 May 25; 31(5):758-64. PubMed ID: 18692273
    [Abstract] [Full Text] [Related]

  • 19. CSF Abeta42, Tau and phosphorylated Tau, APOE epsilon4 allele and MCI type in progressive MCI.
    Herukka SK, Helisalmi S, Hallikainen M, Tervo S, Soininen H, Pirttilä T.
    Neurobiol Aging; 2007 Apr 25; 28(4):507-14. PubMed ID: 16546302
    [Abstract] [Full Text] [Related]

  • 20. Prediction of Alzheimer's disease using a cerebrospinal fluid pattern of C-terminally truncated beta-amyloid peptides.
    Höglund K, Hansson O, Buchhave P, Zetterberg H, Lewczuk P, Londos E, Blennow K, Minthon L, Wiltfang J.
    Neurodegener Dis; 2008 Apr 25; 5(5):268-76. PubMed ID: 18309230
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.